Summary
- During the past six months, TG Therapeutics is demonstrating the behavior of a bioscience stock operating at a growth inflection.
- TG will report Phase 3 data of the ublituximab and umbralisib combination for non-Hodgkin lymphoma and chronic lymphocytic leukemia by mid-2020.
- I forecast that the aforesaid combination will deliver strong clinical outcomes and thereby position the bulls to enjoy the most vigorous rally in the history of this stock.
- Looking for more? I update all of my investing ideas and strategies to members of Integrated BioSci Investing. Start your free trial today ยป

When it's raining gold, reach for a bucket, not a thimble. - Warren Buffett
It is not unusual in bioscience investing to observe a stock that remains dormant for years and thereby tests the investor's patience to the extreme. Nonetheless, all bets are off when a series of powerful catalysts approach to galvanize the bulls for a historic run. TG Therapeutics (TGTX) epitomizes the aforementioned phenomenon. Despite that shares are trading on an uptrend for the past six months, the stock remains relatively flat for the past two years. Since TG will report data for its lead molecules (ublituximab, umbralisib), I strongly believe that this stock is positioned for a substantial rally. In this research, I'll present a fundamental analysis of TG and provide my expectation of this Philip Fisher growth equity.
Figure 1: TG Therapeutics stock chart (Source: StockCharts)
About The Company
As usual, I'll deliver a brief corporate overview for new investors. If you are familiar with the firm, I suggest that you skip to the subsequent section. Headquartered in New York City, TG Therapeutics is focused on the innovation and commercialization of stellar medicines to service unmet needs in blood cancers and autoimmune diseases. There are two late-stage franchises - ublituximab (TG-1101 or "ubli") and umbralisib (TGR-1202 or "umbra") - powering the pipeline.
As a novel antibody, ubli inhibits CD20 found on B-lymphocytes. Available as an oral formulation, umbra suppresses PI3K delta found abundantly in blood cancer cells like B-lymphocytes. Given that PI3K delta plays crucial roles in cancer cell's survival and multiplication, ubli essentially halts cancers at its root. As such, I believe that the mechanism of action of ubli and umbra yields strong efficacy against blood cancers.
Figure 2: Therapeutic pipeline (Source: TG Therapeutics)

